Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Pharmacoeconomics|May 27, 1999
Willingness to pay as a measure of health benefitsM V Bala, J A Mauskopf, L L WoodPharmacotherapy|March 1, 1997
Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence modelD M Grant, J A Mauskopf, L Bell, et al.American Journal of Public Health|May 1, 1993
Potential health benefits of nutrition label changesG A Zarkin, N Dean, J A Mauskopf, et al.Medical Care|April 1, 1995
Estimating the value of a generic quality-of-life measureJ A Mauskopf, R Austin, L P Dix, et al.The Journal of Clinical Psychiatry|October 3, 1999
Annual health outcomes and treatment costs for schizophrenia populationsJ A Mauskopf, K David, D L Grainger, et al.Pharmacoeconomics|February 6, 1998
The role of cost-consequence analysis in healthcare decision-makingJ A Mauskopf, J E Paul, D M Grant, et al.Medical Care|September 1, 1996
Estimating the dollar value of health outcomes from drug-abuse interventionsM T French, J A Mauskopf, J L Teague, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 3, 2000
Impact of zidovudine-based triple combination therapy on an AIDS drug assistance programJ A Mauskopf, J M Tolson, K N Simpson, et al.The Journal of Clinical Psychiatry|December 1, 1996
Functional status in depressed patients: the relationship to disease severity and disease resolutionJ A Mauskopf, G P Simeon, M A Miles, et al.JAMA|July 10, 1996
Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screeningJ A Mauskopf, J E Paul, D S Wichman, et al.Pageof 3